Skip to main content
. 2024 Feb 26;43:101918. doi: 10.1016/j.tranon.2024.101918

Fig. 10.

Fig. 10

Drug sensitivity analysis. (A-F) Bortezomib, Erlotinib, Nilotinib, Gefitinib, Sorafenib, and Paclitaxel have higher IC50 values in the high-risk group. A: Bortezomib; B: Erlotinib; C: Nilotinib; D: Gefitinib; E: Sorafenib; F: Paclitaxel (G) Dasatinib has a higher IC50 value in the low-risk patients.